Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
0.7535
-0.0430 (-5.40%)
At close: Jun 18, 2026, 4:00 PM EDT
0.7523
-0.0012 (-0.16%)
After-hours: Jun 18, 2026, 4:10 PM EDT
Celularity Revenue
In the year 2025, Celularity had annual revenue of $26.55M, down -51.03%. Celularity had revenue of $4.10M in the quarter ending December 31, 2025, a decrease of -77.37%.
Revenue (ttm)
$37.98M
Revenue Growth
-44.88%
P/S Ratio
0.82
Revenue / Employee
$230,870
Employees
115
Market Cap
21.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.55M | -27.67M | -51.03% |
| Dec 31, 2024 | 54.22M | 31.45M | 138.11% |
| Dec 31, 2023 | 22.77M | 4.80M | 26.68% |
| Dec 31, 2022 | 17.98M | -3.36M | -15.75% |
| Dec 31, 2021 | 21.34M | 7.06M | 49.43% |
| Dec 31, 2020 | 14.28M | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 12.88M |
| Marker Therapeutics | 3.55M |
| Lipocine | 2.00M |
| Pluri | 1.08M |
| VYNE Therapeutics | 454.00K |
| Allarity Therapeutics | 345.00K |
| Neuphoria Therapeutics | -13.27K |
CELU News
- 16 days ago - Celularity announces cenplacel-L availability for investigational use in Florida - TheFly
- 16 days ago - Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies - GlobeNewsWire
- 16 days ago - Celularity Releases CEO Letter to Shareholders - GlobeNewsWire
- 17 days ago - Celularity Appoints Rick Gonzalez as Chief Commercial Officer - GlobeNewsWire
- 21 days ago - Celularity Receives Nasdaq Notice Regarding Form 10-Q - GlobeNewsWire
- 7 weeks ago - Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - GlobeNewsWire
- 7 weeks ago - Celularity Annual report: Q4 2025 - Filings
- 7 weeks ago - NEXGEL Appoints Ian Blackman as Chief Financial Officer - GlobeNewsWire